❌ SB198
Prohibit certain actions re: reimbursing 340B covered entities
Current Status: In Senate Committee (Health)
Summary
The bill prohibits drug manufacturers, repackagers, and third-party logistics providers from denying, restricting, or limiting the acquisition and delivery of 340B drugs to 340B covered entities. It also prevents these entities from requiring claims or utilization data from 340B grantees as a condition for drug acquisition or delivery. Violations can result in civil penalties and administrative actions.
Rationale
The bill imposes restrictions on drug manufacturers and health plan issuers, which conflicts with the Libertarian principles of free markets and minimal government intervention. It also creates potential government overreach in regulating the pharmaceutical industry, which is contrary to both LP and LPO platforms.
Risks and Concerns
- Increased government control over the pharmaceutical industry
- Potential for unintended consequences affecting drug availability
- Creation of a precedent for further regulatory measures